Adrenocortical carcinoma: Surgical progress or status quo?

Archives of Surgery

Volumn 136, Issue 5, 2001, Pages 543-549

  Kendrick, Michael L ^a   Lloyd, Ricardo ^a   Erickson, Lori ^a   Farley, David R ^a   Grant, Clive S ^a   Thompson, Geoffrey B ^a   Rowland, Charles ^a   Young Jr , William F ^a   Van Heerden, Jon A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; MITOTANE;

ADOLESCENT; ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0035022726     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.136.5.543     Document Type: Article

References (24)

1. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy
2. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
3. Treatment of adrenal carcinomas
4. Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma?
5. Incidental asymptomatic adrenal masses detected by computed tomographic scanning: Is operation required?
6. Adrenal cortical carcinoma: A continuing challenge
7. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
8. Morphologic characteristics of benign and malignant adrenocortical tumors
9. Pathologic features of prognostic significance in adrenocortical carcinoma
10. The pathology of adrenocortical neoplasia: A correlated structural and functional approach to the diagnosis of malignant disease
11. Cancer of the adrenal cortex: The natural history, prognosis and treatment in a study of fifty-five cases
12. Adrenal cortical carcinoma
13. Adrenocortical carcinoma
14. Adrenal cortical carcinoma in Norway
15. An eleven-year experience with adrenocortical carcinoma
16. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
17. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer
18. The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic implications of serum level monitoring
19. Laparoscopic adrenalectomy: New gold standard
20. Laparoscopic adrenalectomy for cancer
21. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma
22. Can adrenal incidentalomas be safely observed?
23. Adrenal incidentaloma